Kineret Evrópusambandið - íslenska - EMA (European Medicines Agency)

kineret

swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - Ónæmisbælandi lyf - rheumatoid arthritis (ra)kineret is indicated in adults for the treatment of the signs and symptoms of ra in combination with methotrexate, with an inadequate response to methotrexate alone. covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml. periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret ætti að gefa í ásamt colchicine, ef viðeigandi. still’s diseasekineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of still’s disease, including systemic juvenile idiopathic arthritis (sjia) and adult-onset still’s disease (aosd), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (nsaids) or glucocorticoids. kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (dmards).

Rilonacept Regeneron (previously Arcalyst) Evrópusambandið - íslenska - EMA (European Medicines Agency)

rilonacept regeneron (previously arcalyst)

regeneron uk limited - rilonacept - cryopyrin-Í tengslum reglubundið heilkennum - Ónæmisbælandi lyf - rilonacept regeneron er ætlað fyrir meðferð cryopyrin-í tengslum reglubundið heilkennum (hÚfur) með alvarlega einkenni, þar á meðal ættingja kalt farartæki-æsandi heilkenni (fcas) og muckle-wells heilkenni (mws), í fullorðna og börn sem eru 12 ára og eldri.

Ngenla Evrópusambandið - íslenska - EMA (European Medicines Agency)

ngenla

pfizer europe ma eeig - somatrogon - growth and development - sterum og undirstÚku hormÓn og hliÐstÆÐum - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

Norditropin FlexPro Stungulyf, lausn 5/1,5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin flexpro stungulyf, lausn 5/1,5 mg/ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 5/1,5 mg/ml

Norditropin FlexPro Stungulyf, lausn 15/1,5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin flexpro stungulyf, lausn 15/1,5 mg/ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 15/1,5 mg/ml

Norditropin FlexPro Stungulyf, lausn 10/1,5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin flexpro stungulyf, lausn 10/1,5 mg/ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 10/1,5 mg/ml

Norditropin NordiFlex Stungulyf, lausn í áfylltum lyfjapenna 5 mg /1,5 ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin nordiflex stungulyf, lausn í áfylltum lyfjapenna 5 mg /1,5 ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn í áfylltum lyfjapenna - 5 mg /1,5 ml

Norditropin NordiFlex Stungulyf, lausn í áfylltum lyfjapenna 15 mg/1,5 ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin nordiflex stungulyf, lausn í áfylltum lyfjapenna 15 mg/1,5 ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn í áfylltum lyfjapenna - 15 mg/1,5 ml

Norditropin NordiFlex Stungulyf, lausn í áfylltum lyfjapenna 10 mg/1,5 ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin nordiflex stungulyf, lausn í áfylltum lyfjapenna 10 mg/1,5 ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn í áfylltum lyfjapenna - 10 mg/1,5 ml

Waylivra Evrópusambandið - íslenska - EMA (European Medicines Agency)

waylivra

akcea therapeutics ireland limited - volanesorsen járn - hyperlipoproteinemia type i - Önnur fitu breyta lyfjum - waylivra er ætlað sem viðbót til að mataræði í fullorðinn sjúklinga með erfðafræðilega staðfest ættingja chylomicronemia heilkenni (gegn) og í mikilli hættu fyrir lyf og sem svar við mataræði og þríglýseríða lækka meðferð hefur verið ófullnægjandi.